KIMBERLY HARDIN: Open Payments
NPI 1841392784 · NEW ALBANY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,822 in 128 payments from 31 companies in 2025. Trend: 2023 $2,938 · 2024 $2,408 · 2025 $2,822
Food & beverage: $2,484Education: $338
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $388 |
| Novartis Pharmaceuticals Corporation | 15 | $264 |
| E.R. Squibb & Sons, L.L.C. | 16 | $256 |
| Gilead Sciences, Inc. | 8 | $187 |
| PFIZER INC. | 9 | $183 |
| Merck Sharp & Dohme LLC | 9 | $180 |
| Celgene Corporation | 5 | $136 |
| Eisai Inc. | 7 | $126 |
| Lilly USA, LLC | 5 | $107 |
| Janssen Biotech, Inc. | 4 | $95 |
Products named: Trodelvy, KEYTRUDA, OPDIVO, PADCEV, KISQALI, REBLOZYL, Lenvima, ENHERTU.
Industry payments across MS — which companies pay providers there.
